Correlation Between Scholar Rock and Monopar Therapeutics
Can any of the company-specific risk be diversified away by investing in both Scholar Rock and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Scholar Rock and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Scholar Rock Holding and Monopar Therapeutics, you can compare the effects of market volatilities on Scholar Rock and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Scholar Rock with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Scholar Rock and Monopar Therapeutics.
Diversification Opportunities for Scholar Rock and Monopar Therapeutics
0.17 | Correlation Coefficient |
Average diversification
The 3 months correlation between Scholar and Monopar is 0.17. Overlapping area represents the amount of risk that can be diversified away by holding Scholar Rock Holding and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Scholar Rock is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Scholar Rock Holding are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Scholar Rock i.e., Scholar Rock and Monopar Therapeutics go up and down completely randomly.
Pair Corralation between Scholar Rock and Monopar Therapeutics
Given the investment horizon of 90 days Scholar Rock Holding is expected to under-perform the Monopar Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Scholar Rock Holding is 3.29 times less risky than Monopar Therapeutics. The stock trades about -0.23 of its potential returns per unit of risk. The Monopar Therapeutics is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest 3,352 in Monopar Therapeutics on November 27, 2024 and sell it today you would earn a total of 247.00 from holding Monopar Therapeutics or generate 7.37% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Scholar Rock Holding vs. Monopar Therapeutics
Performance |
| Timeline |
| Scholar Rock Holding |
| Monopar Therapeutics |
Scholar Rock and Monopar Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Scholar Rock and Monopar Therapeutics
The main advantage of trading using opposite Scholar Rock and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Scholar Rock position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.| Scholar Rock vs. Revolution Medicines | Scholar Rock vs. Black Diamond Therapeutics | Scholar Rock vs. Passage Bio | Scholar Rock vs. Monte Rosa Therapeutics |
| Monopar Therapeutics vs. Anebulo Pharmaceuticals | Monopar Therapeutics vs. Acrivon Therapeutics, Common | Monopar Therapeutics vs. Pmv Pharmaceuticals | Monopar Therapeutics vs. Molecular Partners AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Complementary Tools
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |